Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 5/2018

01-05-2018 | Research Article

PrediCTC, liquid biopsy in precision oncology: a technology transfer experience in the Spanish health system

Authors: L. Alonso-Alconada, J. Barbazan, S. Candamio, J. L. Falco, C. Anton, C. Martin-Saborido, G. Fuster, M. Sampedro, C. Grande, R. Lado, L. Sampietro-Colom, E. Crego, S. Figueiras, L. Leon-Mateos, R. Lopez-Lopez, M. Abal

Published in: Clinical and Translational Oncology | Issue 5/2018

Login to get access

Abstract

Purpose

Management of metastatic disease in oncology includes monitoring of therapy response principally by imaging techniques like CT scan. In addition to some limitations, the irruption of liquid biopsy and its application in personalized medicine has encouraged the development of more efficient technologies for prognosis and follow-up of patients in advanced disease.

Methods

PrediCTC constitutes a panel of genes for the assessment of circulating tumor cells (CTC) in metastatic colorectal cancer patients, with demonstrated improved efficiency compared to CT scan for the evaluation of early therapy response in a multicenter prospective study. In this work, we designed and developed a technology transfer strategy to define the market opportunity for an eventual implementation of PrediCTC in the clinical practice.

Results

This included the definition of the regulatory framework, the analysis of the regulatory roadmap needed for CE mark, a benchmarking study, the design of a product development strategy, a revision of intellectual property, a cost-effectiveness study and an expert panel consultation.

Conclusion

The definition and analysis of an appropriate technology transfer strategy and the correct balance among regulatory, financial and technical determinants are critical for the transformation of a promising technology into a viable technology, and for the decision of implementing liquid biopsy in the monitoring of therapy response in advanced disease.
Appendix
Available only for authorised users
Literature
1.
2.
Sargent D, Sobrero A, Grothey A, O’Connell MJ, Buyse M, Andre T, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009;27(6):872–7.CrossRefPubMedPubMedCentral
3.
Brandi G, De Lorenzo S, Nannini M, Curti S, Ottone M, Dall’Olio FG, et al. Adjuvant chemotherapy for resected colorectal cancer metastases: literature review and meta-analysis. World J Gastroenterol. 2016;22(2):519–33.CrossRefPubMedPubMedCentral
4.
Van Cutsem E, Verheul HM, Flamen P, Rougier P, Beets-Tan R, Glynne-Jones R, et al. Imaging in colorectal cancer: progress and challenges for the clinicians. Cancers (Basel). 2016;8(9):81.CrossRef
5.
6.
Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail GY, et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol. 2009;20(7):1223–9.CrossRefPubMed
7.
Negin BP, Cohen SJ. Circulating tumor cells in colorectal cancer: past, present, and future challenges. Curr Treat Options Oncol. 2010;11(1–2):1–13.CrossRefPubMed
8.
Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail GY, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(19):3213–21.CrossRefPubMed
9.
Alix-Panabières C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem. 2013;59(1):110–8.CrossRefPubMed
10.
Barbazan J, Muinelo-Romay L, Vieito M, Candamio S, Diaz-Lopez A, Cano A, et al. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer. Int J Cancer. 2014;135(11):2633–43.CrossRefPubMed
11.
Vidal Insua Y, Camara J, Vazquez EB, Fernandez A, Rivera F, Silva MJVV, et al. Predicting outcome and therapy response in mCRC patients using an indirect method for CTCs detection by a multigene expression panel: a multicentric prospective validation study. Int J Mol Sci. 2017;18(6):1265.CrossRefPubMedCentral
12.
Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006;12(14):4218–24.CrossRefPubMed
13.
de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14(19):6302–9.CrossRefPubMed
14.
Lankiewicz S, Zimmermann S, Hollmann C, Hillemann T, Greten TF. Circulating tumour cells as a predictive factor for response to systemic chemotherapy in patients with advanced colorectal cancer. Mol Oncol. 2008;2(4):349–55.CrossRefPubMedPubMedCentral
15.
Anton C, Abal M, Alonso-Alconada L, Candamio S, Lopez-Lopez R, Martin-Saborido C. Monitoring treatment response in metastatic colorectal cancer: economic evaluation of PrediCTC® versus CT scan (submitted).
16.
Tan CRC, Zhou L, El-Deiry WS. Circulating tumor cells versus circulating tumor dna in colorectal cancer: pros and cons. Curr Colorectal Cancer Rep. 2016;12(3):151–61.CrossRefPubMedPubMedCentral
Metadata
Title
PrediCTC, liquid biopsy in precision oncology: a technology transfer experience in the Spanish health system
Authors
L. Alonso-Alconada
J. Barbazan
S. Candamio
J. L. Falco
C. Anton
C. Martin-Saborido
G. Fuster
M. Sampedro
C. Grande
R. Lado
L. Sampietro-Colom
E. Crego
S. Figueiras
L. Leon-Mateos
R. Lopez-Lopez
M. Abal
Publication date
01-05-2018
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 5/2018
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1760-9

Other articles of this Issue 5/2018

Clinical and Translational Oncology 5/2018 Go to the issue

Brief Research Article

Mucinous adenocarcinoma on perianal fistula. A rising entity?

Research Article

Plantar melanoma is associated with certain poor prognostic histopathological factors, but not correlated with nodal involvement, recurrence, and worse survival

Review Article

Ki67 targeted strategies for cancer therapy

Brief Research Article

Modified staging system for pulmonary carcinoids on the basis of lung cancer TNM system

Research Article

Nutritional support and parenteral nutrition in cancer patients: an expert consensus report

Research Article

Urinary cell-free DNA as a prognostic marker for KRAS-positive advanced-stage NSCLC
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits